/ Credibility Index / Ro (Roman / Rory / Zero)
Ro (Roman / Rory / Zero)
DTC Telehealth · DTC telehealth — multi-vertical
C+
Mixed (C+) — Aesthetic Credibility Grade
Ro operates DTC telehealth across men's health (Roman), women's health (Rory), and weight loss (Zero). Mid-tier credentialing on aesthetic-adjacent services. The 2024 GLP-1 weight-loss product launch produced revenue growth but FDA scrutiny.
64
Composite / 100
Where this grade comes from.
Practitioner Credentialing
C+
Injury / Complication Rate
C
Regulatory Track Record
C
Pricing Transparency
B-
Aftercare Quality
C
Key events & disclosures.
- VC-backed
- Zero GLP-1 weight-loss product launch 2023
- FDA scrutiny of compounded GLP-1
- 2022 $7B valuation; secondary trades at meaningful discount
/ Best for
Customers seeking convenient telehealth access to specific medications.
/ Watch out for
Compounded GLP-1 regulatory environment is uncertain. Limited in-person aesthetic services.